AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04943549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
Study NCT04939090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO
Study NCT04939090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Given PO
Study NCT04939090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04939090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05783089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin CAR-T cells
Description: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
Study NCT04961515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.
Study NCT04961515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)
Study NCT04961515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
Study NCT05972590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological samples collection (blood + feces)
Description: Blood + stools samples will be collected from each volunteer
Study NCT06567106 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No ultrasound application
Description: No ultrasound application to the participant.
Study NCT05673603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet
Study NCT04638127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREEMIE PROGRESS
Description: PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
Study NCT04638127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: usual care and welcome videos
Study NCT04920695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Pulmonary vasodilator (gas).
Study NCT04920695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: medical grade normoxic gas (FiO2 = 0.21)
Study NCT05612958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKM-410
Description: Injection up to 2.0ml
Study NCT05612958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm ULTRA PLUS XC 1.0ml
Description: Injection up to 2.0ml
Study NCT05022992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
Study NCT05547971 — intervention group
Intervention type: RADIATION
Intervention: intensity-modulated radiation therapy
Description: The patients got intensity-modulated radiation therapy during observation
Study NCT05249777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0069 hard capsule
Description: TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
Study NCT05249777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD0069 Placebo
Description: TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
Study NCT05026229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib plus consolidation chemotherapy with vincristine and prednisone
Description: After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
Study NCT05026229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
Description: After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
Study NCT05341388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA cognitive evaluation test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
Study NCT05341388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BDNF levels
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
Study NCT05341388 — intervention group
Intervention type: OTHER
Intervention: SF-36 test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
Study NCT05341388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric depression test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
Study NCT05171855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
Study NCT06569719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy
Description: Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
Study NCT05877365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Process 21-Day Purification Program
Description: Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
Study NCT05395416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA+HEC110114
Description: administered orally once daily for 12 weeks
Study NCT04716712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
Study NCT05949944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combination with CHOP
Description: Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
Study NCT05395416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily for 12 weeks
Study NCT05419739 — intervention group
Intervention type: OTHER
Intervention: Glasgow coma scale
Description: This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
Study NCT06449703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
Study NCT06449703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xultophy®
Description: Xultophy®
Study NCT06214494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restricted High Intensity Treadmill Training
Description: Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
Study NCT06214494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HITT
Description: High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
Study NCT04842344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R
Description: extracorporeal carbon dioxide removal
Study NCT04940598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval exercise
Description: HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
Study NCT04940598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-exercise control group
Description: No-exercise control group
Study NCT04841668 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
Study NCT04374903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ & AZ vs HCQ+SIR
Description: Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
Study NCT05187338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab +pembrolizumab +durvalumab
Description: This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.
Study NCT06340555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GUIA ATENCION MULTIDISCIPLINAR SANT BOI
Description: Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
Study NCT06340555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USUAL CARE
Description: Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
Study NCT04816396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reminiscence Therapy
Description: Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
Study NCT04544618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality operating room simulation
Description: The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
Study NCT04716712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching identical placebo in packaging, appearance, and taste.
Study NCT04883164 — intervention group
Intervention type: OTHER
Intervention: Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
Description: Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
Study NCT05138796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral capsules)
Description: TP-05 (lotilaner oral capsules)
Study NCT05138796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match TP-05 (lotilaner oral capsules)
Study NCT05993234 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC.
Study NCT06433050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
Study NCT06433050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
Study NCT05792436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-min interval oscillometric method
Description: Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period.
Study NCT05792436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial catheterization method
Description: During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
Study NCT05719220 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group preoperative pelvic floor training
Description: Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
Study NCT05552729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
Study NCT05879315 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fall risk prevention in hospital
Description: All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
Study NCT04982549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (intravenous infusion)
Study NCT04982549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care
Study NCT04982549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care
Study NCT04982549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care
Study NCT04982549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
Study NCT05632250 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ConvaFoam
Description: ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
Study NCT05970055 — intervention group
Intervention type: PROCEDURE
Intervention: elective surgery
Description: All elective surgical procedures performed under the study period will be included.
Study NCT04846686 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placenta pathological examination
Description: a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
Study NCT06144034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
Study NCT06144034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
Study NCT05245500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1719
Description: MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days
Study NCT05909202 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: Nature-based non-immersive VR program
Study NCT05731375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 31-MRS at 7 Tesla (T)
Description: 31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.